Does Dupixent Help with Asthma Symptoms?
Yes, Dupixent (dupilumab) reduces asthma symptoms in patients with moderate-to-severe eosinophilic asthma or asthma with type 2 inflammation. Approved by the FDA in 2017 for patients aged 6 years and older whose asthma is not controlled by inhaled steroids, it targets IL-4 and IL-13 signaling to lower inflammation. Clinical trials showed it cut severe exacerbations by 46-67% and improved lung function (FEV1) by 320-340 mL versus placebo.[1][2]
How Does Dupixent Work for Asthma?
Dupixent blocks two key proteins driving type 2 inflammation, common in 50-70% of asthma cases. This reduces airway swelling, mucus production, and eosinophil activity. Patients report less wheezing, shortness of breath, and nighttime awakenings within 2-4 weeks, with peak benefits by 12 weeks.[1][3]
Who Qualifies for Dupixent in Asthma?
It's for those with uncontrolled asthma despite standard therapies, confirmed by blood eosinophils ≥150 cells/μL or FeNO ≥20 ppb. Not for acute attacks or patients without type 2 markers. Dosing starts at 400 mg loading dose, then 200 mg every 2 weeks via subcutaneous injection.[1][2]
What Do Clinical Trials Show on Symptom Relief?
In the LIBERTY ASTHMA QUEST trial (3,532 patients), Dupixent improved symptoms by 47% on a standardized asthma control questionnaire versus 31% with placebo. The QUEST trial reported 59% reduction in exacerbations needing steroids. Long-term data from open-label extensions confirm sustained relief up to 3 years, with 75% of patients reducing oral steroid use.[2][4]
Common Side Effects and Risks
Injection-site reactions occur in 10-18% of users. Other issues include joint pain (3-5%), eosinophilia flares (1-2%), and rare helminth infections. No increased anaphylaxis risk. Monitor for eye problems like conjunctivitis (2-10%). It's safe in pregnancy category unknown but used in trials without major fetal harm signals.[1][3]
How Does It Compare to Other Asthma Treatments?
| Treatment | Mechanism | Exacerbation Reduction | Symptom Improvement | Cost (Annual, Approx.) |
|-----------|-----------|-------------------------|----------------------|-------------------------|
| Dupixent | IL-4/IL-13 blocker | 46-67% | High (FEV1 +320 mL) | $40,000+ [5] |
| Xolair (omalizumab) | IgE blocker | 25-50% | Moderate | $20,000-$30,000 |
| Nucala (mepolizumab) | IL-5 blocker | 47-53% | Moderate (FEV1 +100-200 mL) | $30,000+ |
| Inhaled steroids + LABA | Broad anti-inflammatory | 20-40% | Baseline control | $500-$2,000 |
Dupixent excels in type 2-dominant asthma but requires specialist oversight. No head-to-head trials exist; choice depends on biomarkers.[2][6]
When Does Dupixent's Patent Expire?
Core U.S. patents on Dupixent for asthma expire in 2029-2031, with method-of-use extensions to 2035. Challenges from generics are ongoing, but no biosimilars approved yet. Check DrugPatentWatch.com for updates on litigation and Paragraph IV filings.[7]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761055s047lbl.pdf
[2] NEJM (2016): https://www.nejm.org/doi/full/10.1056/NEJMoa1604092
[3] Dupixent Prescribing Info: https://www.dupixent.com/asthma
[4] Lancet Respir Med (2020): https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30052-3/fulltext
[5] GoodRx pricing data (2023)
[6] ATS Guidelines: https://www.atsjournals.org/doi/full/10.1164/rccm.202202-0398ST
[7] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/DUPIXENT